ANTIHYPERTENSIVE MEDICATIONS NURSING CARE

1. Angiotensin Converting Enzyme Inhibitors : CAPTOPRIL

 After washing hands, 12 correct.

 Monitor vital signs, especially blood pressure.
 Monitor for signs of angioedema, monitor blood sodium and potassium levels
during treatment
 Inform the patient that it may take several weeks for the desired therapeutic
effects to occur.
 Warn the patient not to take any supplements containing potassium.
 If there is an increase in potassium levels in the blood, take arterial blood gases
to rule out possible metabolic acidosis.

2. Angiotensin II Receptor Antagonist : LOZARTAN

 After washing hands, 12 correct

 Monitor vital signs, especially heart rate and blood pressure.
 Monitor photosensitivity, rashes, changes in the central nervous system.
 Take electrocardiograms on the patient to see if changes occur in the condition
of the heart.
 Inform the patient not to change position so abruptly because it may cause
dizziness or cause orthostatic hypotension.
 Educate the patient.
 Suggest that the patient have some laboratory tests.

3. Calcium Channel Blockers : AMLODIPINO

 After washing hands, 12 correct times, taking blood pressure before and
after administration of the medication.
 Use caution when administering IV due to interaction with beta blockers
 Monitor ECG for AV block (may increase PR interval.
 Inquire about atrioventricular conduction disorders due to the risk of
blockage due to myocardial and sinus node depression.
 monitor for the presence of adverse reactions.

ANTICOAGULANT MEDICATIONS NURSING CARE

1) Low molecular weight heparin: ENOXAPARIN

 Administer after lunch

 Monitor clotting time
 Observe presence of hum
 Monitor for signs of digestive disorders
 Platelet count value, presence of bleeding, abdominal pain, dyspepsia,
gastritis, constipation, skin disorders
 In the administration of fibrinolytics, constant monitoring for possible
adverse reactions
 Monitor for the presence of possible neurological signs that may be due to a
cerebral hemorrhage.
 If you intend to use streptokinase, you must ask the patient if they have
been administered it in the previous 12 months; if so, it should not be used
due to the danger of producing an adverse reaction.
 During fibrinolytic treatment up to two days later, no drug should be
administered IM.
 During administration in myocardial infarction, the appearance of
arrhythmias should be monitored.